La Trobe
1159101_Fonseka,P_2020.pdf (1.88 MB)

Combinatorial treatment of curcumin or silibinin with doxorubicin sensitises high-risk neuroblastoma

Download (1.88 MB)
journal contribution
posted on 20.05.2021, 05:07 by Hewafonsekage Fonseka, Lahiru Gangoda, Mohashin Pathan, Angela Di Giannatale, Suresh Mathivanan
Neuroblastoma is a pediatric cancer of the sympathetic nervous system. Using various parameters including stage of the disease, amplification status of N-Myc, DNA index and histopathology, neuroblastoma can be stratified into low- and high-risk groups. Recent advances in treatment have significantly improved the survival rate of lowrisk neuroblastoma patients. However, the overall survival rate of high-risk neuroblastoma group, especially N-Myc amplified patients, is poor. Moreover, the survivors of both low- and high-risk neuroblastoma manifest adverse side effects to chemotherapy and thus their quality of life is impaired. Considering all these factors, there is an urgent need to develop therapeutic strategies with natural compounds to improve the survival rate and to reduce the side effects. In this study, we hypothesised that the mesenchymal nature of neuroblastoma cells is a reason, at least in part, for the aggressive and treatment resistant phenotype.

History

Publication Date

13/03/2020

Journal

Journal of Cancer Metastasis and Treatment

Volume

6

Article Number

7

Pagination

11p.

Publisher

OAE Publishing

ISSN

2394-4722

Rights Statement

The Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.

Usage metrics

Journal Articles

Categories

Licence

Exports